丙型肝炎防治指南(2022年版)

Guideline for the prevention and treatment of hepatitis C(2022 version)

为了规范和更新丙型肝炎的预防、诊断和抗病毒治疗,实现世界卫生组织提出的"2030年消除病毒性肝炎公共卫生危害"目标,中华医学会肝病学分会和感染病学分会于2019年组织国内有关专家,以国内外丙型肝炎病毒感染的基础和临床研究进展为依据,结合现阶段我国的实际情况,更新形成了《丙型肝炎防治指南(2019年版)》,为丙型肝炎的预防、诊断和治疗提供了重要依据。2019年年底以来,丙型肝炎的筛查及管理策略有进一步的更新,越来越多的直接抗病毒药物,特别是包括国产企业研发生产在内的泛基因型方案纳入国家基本医疗保险目录,药物价格可及性明显增加,中华医学会肝病学分会和感染病学分会于2022年组织国内有关专家对丙型肝炎筛查及治疗的推荐意见进行再次更新。

In order to update the prevention,diagnosis and antiviral therapy for hepatitis C and to achieve the World Health Organization’s goal of eliminating viral hepatitis as a public health threat by 2030;Chinese Medical Association,the Chinese Society of Hepatology,and the Society of Infectious Diseases organized relevant experts in 2019 to update the guidelines for the prevention and treatment of hepatitis C(2019 version)based on the basic and clinical research progress of hepatitis C infection,combined with the present situation of our country,so as to provide an important basis for the prevention,diagnosis and treatment of hepatitis C.Since the end of 2019,the screening and management strategy of hepatitis C has been further updated.More and more direct antiviral agents,especially pan genotypic agents including those developed and produced by domestic enterprises,have been included in the national basic medical insurance directory.The accessibility of drugs has significantly increased.In 2022,experts updated the recommendations on prevention and treatment again.